FDA approves Novartis' Cosentyx for polymyalgia rheumatica
NVS•The FDA approved Novartis' Cosentyx 150 mg to treat adults with polymyalgia rheumatica who have an inadequate response to corticosteroids or cannot tolerate tapering. The approval is Cosentyx's 11th U.S. indication and makes it the first anti-IL-17 biologic approved for the disease.
1. Approval and eligibility
The FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who have an inadequate response to corticosteroids or are unable to tolerate corticosteroid tapering. The approval marks Cosentyx's 11th U.S. indication and makes it the first anti-IL-17 biologic approved for the disease.




